CAMBRIDGE, Mass, December 6, 2023 – Myeloid Therapeutics, Inc. (“Myeloid”), a clinical stage oncology company, has appointed Matthew Maurer, M.D. as Chief Medical Officer. Dr. Maurer is an experienced physician-scientist with over fifteen years of clinical oncology experience as a drug developer and a principal investigator advancing multiple cancer programs through the early and late […]
MT-302 arms myeloid cells with an mRNA-encoded CAR to kill tumor cells expressing TROP2, and trigger an adaptive immune response to metastatic epithelial tumors CAMBRIDGE, Mass, September 12, 2023 – Myeloid Therapeutics, Inc. (“Myeloid”), a clinical stage oncology company, has dosed the first patient with MT-302 in a Phase 1 study for advanced or metastatic […]
Financing accelerates MT-302, the Company’s first clinical candidate for in vivo cell programming, into a Phase 1/2 clinical trial for TROP2+ solid tumors CAMBRIDGE, Mass., May 18, 2023 – Myeloid Therapeutics, Inc. (“Myeloid”), a clinical stage mRNA-immunotherapy company, announced today the completion of a $73 million financing led by Hatteras Investment Partners, with participation from […]
Myeloid Therapeutics Presents Late-Breaking Data on Multiple Platforms at the American Association for Cancer Research (AACR) 2023 Annual Meeting CAMBRIDGE, Mass, April 17, 2023 – Myeloid Therapeutics, Inc. (“Myeloid”), a clinical stage mRNA-immunotherapy company, today announced its presentation of two posters at the American Association for Cancer Research (AACR) Annual Meeting, being held in Orlando, […]
Myeloid Therapeutics and New South Wales (NSW) Government in Australia Announce Collaboration to Design, Build, and Launch State-of-the-Art GMP Manufacturing Facility Dedicated to RNA Immunotherapies – NSW will invest AU $96 million to support the facility design, construction and roll-out – – Myeloid will operate the facility and bring its RNA know-how and leadership to […]
CAMBRIDGE, Mass, January 26, 2023 – Myeloid Therapeutics, Inc. (“Myeloid”), a clinical stage mRNA-immunotherapy company, today announced that management will present at the Guggenheim Healthcare Talks 2023 Oncology Day, being held February 8-9, 2023, in New York, NY. Daniel Getts, Ph.D., CEO of Myeloid, will present a company overview on Wednesday, February 8, 2023, at […]
CAMBRIDGE, Mass, January 5, 2023 – Myeloid Therapeutics, Inc. (“Myeloid”), a clinical stage mRNA-immunotherapy company, today announced that Daniel Getts, Ph.D., CEO of Myeloid, will present at the 41st Annual J.P. Morgan Healthcare Conference taking place January 9-12, 2023, in San Francisco, CA. The company is scheduled to present on Thursday, January 12, 2023, at […]
CAMBRIDGE, Mass, Nov. 10, 2022 /PRNewswire/ — Myeloid Therapeutics, Inc. (“Myeloid”), a clinical stage mRNA-immunotherapy company, today announced that the Company will participate at the Jefferies London Healthcare Conference taking place from November 15-17, 2022 in London. Company management will meet one-on-one with investors during the conference. About Myeloid Therapeutics Myeloid Therapeutics is a clinical […]
Myeloid Therapeutics Presents Update On Myeloid Cell Programming Technologies, Including Non-Human Primate Proof-Of-Concept Data Delivering in vivo mRNA TROP-2 Targeting CAR (MT-302) at Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting -New preclinical data on lead in vivo programming program, MT-302, demonstrates strong expression and favorable safety in myeloid cells following a single administration […]
Myeloid Therapeutics Announces FDA Fast Track Designation for MT-101 for the Treatment of CD5+ Relapsed/Refractory PTCL CAMBRIDGE, Mass, October 27, 2022 – Myeloid Therapeutics, Inc. (“Myeloid”), a clinical-stage mRNA-immunotherapy company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to MT-101 in patients with refractory or relapsed CD5+ peripheral […]